Clinical Study Results
These adverse reactions may or may not be caused by the study drugs. A lot of research
is needed to know whether a drug causes an adverse reaction.
The websites listed at the end of this summary may have other information about adverse
reactions or other medical problems that happened during this study.
How many participants had serious adverse reactions?
Overall, there were 4 out of 26 participants who had serious adverse reactions during
Part A of the study. This was 15.4% of participants.
• There was 1 out of the 13 participants who got durvalumab alone who had at least
1 serious adverse reaction. This was 7.7% of participants. This serious adverse
reaction led to the death of this participant.
• There were 3 out of the 13 participants who got durvalumab and tremelimumab who
had at least 1 serious adverse reaction. This was 23.1% of participants.
Serious adverse reactions
Durvalumab Durvalumab and
alone tremelimumab
(out of 13 (out of 13
participants) participants)
Abnormal liver function 0.0% (0) 15.4% (2)
Decreased number of platelets, cells that help blood
0.0% (0) 15.4% (2)
to clot
Increased bilirubin, a yellow substance made by the
0.0% (0) 7.7% (1)
liver after breakdown of old red blood cells
Cell damage causing muscle weakness and pain 7.7% (1) 0.0% (0)
How many participants had adverse reactions?
There were 21 out of 26 participants who had at least 1 adverse reaction. This was 80.8%
of participants.
• There were 9 out of the 13 participants who got durvalumab alone who had adverse
reactions during the study. This was 69.2% of participants.
• There were 12 out of the 13 participants who got durvalumab and tremelimumab who
had adverse reactions during the study. This was 92.3% of participants.
Overall, there were 4 out of 26 participants who had at least 1 adverse reaction that led to
stopping treatment. This was 15.4% of participants.
6